Edition:
United States

GlaxoSmithKline PLC (GSK)

GSK on New York Consolidated

42.67USD
26 May 2017
Change (% chg)

$0.10 (+0.23%)
Prev Close
$42.57
Open
$42.84
Day's High
$42.91
Day's Low
$42.58
Volume
4,963,611
Avg. Vol
3,186,808
52-wk High
$45.58
52-wk Low
$37.20

GSK

Chart for GSK

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $104,570.00
Shares Outstanding(Mil.): 2,458.72
Dividend: 0.49
Yield (%): 4.66

Financials

  GSK Industry Sector
P/E (TTM): 48.74 14.27 17.41
EPS (TTM): 0.88 -- --
ROI: 5.27 -7.17 -5.42
ROE: 74.13 -6.63 -4.68

BRIEF-Kuehne und Nagel and GlaxoSmithKline expand partnership with new UK domestic distribution contract

* KUEHNE + NAGEL AND GLAXOSMITHKLINE EXPAND PARTNERSHIP WITH NEW UK DOMESTIC DISTRIBUTION CONTRACT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

May 17 2017

Deals of the day-Mergers and acquisitions

May 12 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday:

May 12 2017

Top-10 Glaxo investor Woodford sells out, criticises board

LONDON British fund manager Neil Woodford said on Friday he had sold out of pharma company GlaxoSmithKline after a "frustrating" stint as an investor spanning more than 15 years.

May 12 2017

UPDATE 2-Top-10 Glaxo investor Woodford sells out, criticises board

* Buys into 'well-managed' Lloyds Banking Group (Adds Glaxo statement)

May 12 2017

Top-10 Glaxo investor Woodford sells out, fires broadside at board

LONDON, May 12 High-profile British fund manager Neil Woodford said on Friday he had sold out of pharmaceutical company GlaxoSmithKline after holding shares in the company for more than 15 years.

May 12 2017

GSK escapes Advair hit for now as second generic bid fails

LONDON GlaxoSmithKline is likely to escape generic competition to its blockbuster lung drug Advair in the United States this year, after a second application for a cut-price equivalent form of the medicine was turned down by U.S. regulators.

May 11 2017

Hikma's generic Advair faces U.S. delay, 2017 approval unlikely

LONDON, May 11 Hikma Pharmaceuticals said on Thursday that U.S. regulators had decided not to approve its generic copy of GlaxoSmithKline's blockbuster lung drug Advair at this time, due to 'major' issues with its application.

May 11 2017

UPDATE 1-UK Stocks-Factors to watch on May 11

May 11 Britain's FTSE 100 index is seen opening 11 points lower on Thursday, according to financial bookmakers, with futures up 0.05 percent ahead of the cash market open.

May 11 2017

UK Stocks-Factors to watch on May 11

May 11 Britain's FTSE 100 index is seen opening 11 points lower on Thursday, according to financial bookmakers. * BHP: Workers at BHP Billiton's, Cerro Colorado copper mine in Chile will strike for 24 hours in the coming weeks to protest recent layoffs and the company's general attitude toward miners, the main union told Reuters on Wednesday. * MYLAN/GLAXO: Generic drug maker Mylan NV on Wednesday said it disagrees with the reasoning behind the U.S. Food and Drug Ad

May 11 2017

BRIEF-GlaxoSmithKline announces positive results for asthma drug study

* Announced positive results from innovative Salford Lung Study (SLS) in asthma

May 05 2017

More From Around the Web

Competitors

Earnings vs. Estimates